A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting

Trial Profile

A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Neratinib (Primary) ; Capecitabine; Lapatinib
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms NALA
  • Sponsors Puma Biotechnology
  • Most Recent Events

    • 02 Aug 2017 Planned End Date changed from 1 May 2018 to 1 Feb 2019.
    • 02 Aug 2017 Planned primary completion date changed from 1 May 2017 to 1 Feb 2019.
    • 06 Jul 2017 According to a Puma Biotechnology media release, primary analysis of PFS will be available during the first half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top